Feature

How to recognize and treat hidden inflammation


 

Glucocorticoids and immunosuppressants

Despite therapeutic intervention, the disease can have a fatal outcome, even if the patient is young, said Dr. Müller-Ladner. Glucocorticoids are the current therapy of choice. The dose is more than 0.5 mg of prednisolone equivalent per kg of body weight. “This usually leads to a rapid improvement in the inflammation. Subsequently, every organ is thoroughly diagnosed to assess the severity of the disease and to plan further treatment steps.”

In the long term, proven immunosuppressants, such as azathioprine, mycophenolate, leflunomide, and methotrexate, can be used, just as for many other chronic inflammatory diseases. Cyclophosphamide or cyclosporine is used more rarely, owing to their side effect profiles.

Because of the B-cell dominance, B-cell–depleting therapy with rituximab is currently a highly effective therapeutic option but one that must be applied for, because such use is off label. “If the body responds well to the medication, organ function often recovers,” said Dr. Müller-Ladner.

This article was translated from the Medscape German edition. A version appeared on Medscape.com.

Pages

Recommended Reading

Vaccination cuts long COVID risk for rheumatic disease patients
MDedge Internal Medicine
Cardiovascular risk score multipliers suggested for rheumatic diseases
MDedge Internal Medicine
Belimumab for pregnant women with lupus: B-cell concerns remain
MDedge Internal Medicine
Best estimates made for hydroxychloroquine retinopathy risk
MDedge Internal Medicine
VEXAS syndrome: More common, variable, and severe than expected
MDedge Internal Medicine
75 years: A look back on the fascinating history of methotrexate and folate antagonists
MDedge Internal Medicine
Systemic sclerosis antibodies show link to interstitial lung disease in RA
MDedge Internal Medicine
Two biomarkers identify high-risk lupus nephritis
MDedge Internal Medicine
Health plans get very poor scores for access to autoimmune drugs
MDedge Internal Medicine
New tool better estimates cardiovascular risk in people with lupus
MDedge Internal Medicine